Latest Kaiser Health News Stories
Saving the lives of people with the bleeding disorder can require high doses of expensive blood-clotting factor. Taxpayers foot much of the bill as manufacturers profit enormously.
California’s health insurers trotted out a heart-healthy character with an ulterior motive — taking a dig at drugmakers.
Legislatures in blue and red states alike are considering proposals that would allow them to import prescription drugs from Canada.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
The Trump administration rolled out a list of actions to attack drug prices, but most dance around the edges.
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR’s Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
Fatalities are climbing in states that have been flooded by the deadly opioid fentanyl, but are remaining flat — or even falling — in many Western states, where the drug has not yet been as common as other parts of the country.
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Genetic testing firms declare bankruptcy and wipe out debt to the federal government.
Researchers estimate that 25 percent of people ages 65 to 69 take at least five prescription drugs to treat chronic conditions. But some doctors are trying to teach others about “deprescribing” or systematically discontinuing medicines that are inappropriate, duplicative or unnecessary.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
Based on research conducted at the University of Michigan’s medical center, a group of surgeons developed a strategy to help post-surgical patients from misusing or abusing their prescription painkillers.
The hurricane closed pharmacies and clinics for a week or longer. Floodwaters spoiled drugs. People who fled to other states couldn’t get their prescriptions filled for HIV medicine.